Straight from the 2011 American Society of Clinical Oncology (ASCO) meeting, renowned expert Dr. Susan M. O’Brien shares breaking news for people living with CLL. In this podcast, she explains recent clinical trial progress for a type of therapy known as Tyrosine Kinase Inhibitors. Two drugs currently in trials - currently called CAL-101 and PCI-32765 - are giving new hope to elderly CLL patients and those who haven’t responded to chemotherapy.
|
Susan M. O'Brien, MD
Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Susan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of...
more >
|
|
|
